CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Crisaborole +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03832010
NCT03832010Phase 4Completed
CompareCT.gov

Proof of Concept Investigation of the Steroid-reducing Effects of Crisaborole in Children

Johns Hopkins University·interventional·Posted Feb 6, 2019·Updated Jul 19, 2024

In Brief

A Phase 4 clinical trial evaluating Crisaborole, Hydrocortisone Ointment, and 2 other interventions for Atopic Dermatitis and Eczema. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Atopic dermatitis, or eczema, is a chronic skin condition affecting many children. Crisaborole is a non-steroid topical medication which is FDA approved for children aged 2 and older for eczema. This research study seeks to investigate whether crisaborole reduces topical steroid use in children with atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Eczema
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 6, 2019
Enrollment StartDec 17, 2019
Primary CompletionFeb 16, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.4 years ago

Interventions

Crisaboroledrug

Participants will be instructed to apply crisaborole to affected areas with eczema.

Hydrocortisone Ointmentdrug

Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.

Triamcinolone ointmentdrug

Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.

Aquaphordrug

Participants will be instructed to moisturize all over the body with Aquaphor.